CCR5 and COVID-19: A phase 1 clinical trial to test the efficacy of maraviroc, an FDA-approved CCR5 antagonist in HIV/AIDS, is also in progress in moderate and severe cases of COVID-19 (ClinicalTrials.gov Identifier: NCT04435522).